The joint venture will focus on generic intravenous drugs and infusion solutions and will make Fresenius Kabi the Indonesian market leader in intravenous generics.

Indonesia is an emerging country in the pharmaceutical business. Demand for healthcare, and thus prescription drugs, has been rising steadily. As a result of a universal healthcare programme, which is set to be introduced in 2014, most of the Indonesian population is expected to have access to modern healthcare by 2019.

As a result of these reforms to healthcare the Indonesian pharmaceutical market is expected to double to reach Euros 7.1 billion by 2018, making this an attractive deal for Fresenius Kabi.

The deal is expected to boost the product pipeline for PT Soho Global Health, while giving Fresenius Kabi access to valuable local manufacturing capabilities and a strong market presence. Fresenius Kabi also intends to use the joint venture as a hub for further expansion into the South East Asia Region.

The companies are expected to finalize the deal in the third quarter of 2013.

Related articles

Fresenius cashes in on drug shortages

Generics companies turn to ‘third tier’ countries

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.